首页|HNF-1β在胰腺导管腺癌中的表达及其诊断价值

HNF-1β在胰腺导管腺癌中的表达及其诊断价值

扫码查看
目的 检测肝细胞核因子1β(hepatocyte nuclear factor 1β,HNF-1β)在胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)组织中的表达并探讨其诊断价值.方法 收集2021-01-2023-01 49例PDAC,采用免疫组化 EnVision 两步法检测 HNF-1β、CK7、CK20、PAX-8、GATA-3、NapsinA、TTF1、ER、PR、NKX3.1 和 RCC 的表达情况,比较各种肿瘤标记物表达的阳性率.结果HNF-1β阳性率为85.7%(42/49),其中45.2%(19/42)的病例为强阳性,14.3%(6/42)的病例为中等阳性,40.5%(17/42)的病例为弱阳性.CK7阳性率为83.7%(41/49).CK20阳性率为 4.1%(2/49).PAX-8、GATA-3、Napsin A、TTF1、ER、PR、NKX3.1 和 RCC 均为阴性表达,阳性率为 0(0/49).结论HNF-1β与其他谱系特异性的肿瘤标志物联合使用,可有助于PDAC的诊断和与其他来源的腺癌的鉴别诊断.
Expression of HNF-1β in pancreatic ductal adenocarcinoma and its diagnostic value
Objective To investigate the expression of Hepatocyte nuclear factor 1β(HNF-1β)in pancreatic ductal adenocarcinoma(PDAC)and its diagnostic value.Methods 49 cases of PDAC were collected from January 2021 to January 2023,and the expressions of HNF-1β,CK7,CK20,PAX-8,GATA-3,NapsinA,TTF1,ER,PR,NKX3.1 and RCC were detected by immunohistochemical EnVision method.The positive rates of various tumor markers were compared.Results The positive rate of HNF-1β was 85.7%(42/49),of which 45.2%(19/42)cases were strongly positive,14.3%(6/42)cases were moderately positive,and 40.5%(17/42)cases were weakly positive.The positive rate of CK7 was 83.7%(41/49).The positive rate of CK20 was 4.1%(2/49).PAX-8,GATA-3,Napsin A,TTF1,ER,PR,NKX3.1 and RCC were all negative,and the positive rate was 0%(0/49).Conclusion HNF-1β combined with other lineage-specific tumor markers may be helpful in the diagnosis of PDAC and differential diagnosis from adenocarcinoma of other origin.

Pancreatic ductal adenocarcinomaHNF-1βTissue microarrayImmunohistochemistry

魏雪、章如松、曹阳、程凯、王璇、马恒辉、饶秋、方茹

展开 >

东部战区总医院病理科,南京 210000

胰腺导管腺癌 HNF-1β 组织芯片 免疫组化

国家自然科学基金

82103192

2024

诊断病理学杂志
北京军区总医院

诊断病理学杂志

CSTPCD
影响因子:0.663
ISSN:1007-8096
年,卷(期):2024.31(1)
  • 22